Cencora Inc.
BioSniper Score
Based on 4 of 6 signals
Market Cap
$52.89B
Cash Runway
24.9 mo
Lead Asset
biopure hx2 reverse osmosis water purification system
Next Catalyst
—
Tracking 16 pipeline candidates for Cencora Inc. · Updated within the last hour.
Go deeper on Cencora Inc. with Spotter
Ask follow-up questions and run a full multi-agent deep dive on COR — live, with citations.
Score breakdownBased on 4 of 6 signals · derived from public data
24.9 months
D/E 23.03 · 0% dilution
No tracked pipeline phase
16 candidates
No upcoming catalysts tracked
1 buy · 3 sells (180d)
Key Financialsas of March 31, 2026
Cash
$2.24B
Quarterly Burn
$2.11B
Revenue
$78.36B
Free Cash Flow
$1.34B
Total Liabilities
$78.25B
Shareholders Equity
$3.40B
Current Ratio
0.95
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (16 candidates)
Showing 10 of 16 candidates. Sign up for full pipeline.
Commercialization & Governance
Commercialization
- Partnerships
- WalgreensBootsEvernorth Health Servicesgroup purchasing organizations (GPOs)pharmaceutical and biotech manufacturers
- Launch Markets
- United StatesEuropeCanadaselect global markets
- Commercial Strategy
- Focus on the global pharmaceutical supply chain providing distribution and value-added services to healthcare providers and pharmaceutical manufacturers; drive executional excellence in core U.S. and international distribution while investing in higher-margin, high-growth adjacencies that support clinical development and commercialization. Key elements include: optimizing and growing U.S. Healthcare Solutions and International Healthcare Solutions; offering value-added services (data analytics, outcomes research, reimbursement and pharmaceutical consulting, regulatory affairs, development consulting, pharmacovigilance, quality management and compliance, logistics, inventory management, pharmacy automation, packaging solutions); programs such as Good Neighbor Pharmacy and Elevate Provider Network; a generic product private label program based in Ireland; investments in warehouse automation, ERP and electronic ordering systems, and cybersecurity; pursuing acquisitions and investments (including the January 2, 2025 acquisition of an 85% interest in Retina Consultants of America) and considering divestitures to align with growth priorities; and exploring use of AI to improve operations.
Governance
- Board Size
- 11
- Independent Pct
- 91%
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,423
Total value held
$50.01B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 19,943,637 | $6.27B |
| vanguard capital management llc | 12,313,459 | $3.87B |
| vanguard portfolio management llc | 9,590,414 | $3.01B |
| state street corp | 9,190,551 | $2.89B |
| fmr llc | 6,686,269 | $2.10B |
| geode capital management, llc | 5,566,044 | $1.75B |
| wellington management group llp | 4,548,612 | $1.43B |
| morgan stanley | 4,531,912 | $1.42B |
| boston partners | 4,482,817 | $1.41B |
| bank of america corp /de/ | 4,138,388 | $1.30B |
Showing top 10 of 1,423 institutional holders of Cencora Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
Who is the CEO of Cencora Inc.?
Dr. Robert P. Mauch Ph.D., PharmD is the chief executive officer of Cencora Inc. (COR).
Where is Cencora Inc. headquartered?
Cencora Inc. (COR) is headquartered in Conshohocken, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on Cencora Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.